He expressed optimism that this growth will continue, driven by the potential approval of lenacapavir as a preventive ...

What is patent evergreening and what does the Indian patent regime tell us about it? Also, go beyond the nugget to know about ...

Major purchases of the most advanced medical equipment and consumables, and cooperation on major infectious diseases such as ...

本次进博会现场，吉利德与中国癌症基金会签订了一项为期三年的战略合作备忘录，以提高晚期乳腺癌患者生存期与生活质量为核心目标，在优化诊疗路径、提升创新药物可及性、科研临床协同发展、用药不良反应监测、癌症监测管理体系等关键维度发力，形成全方位、多层次的癌症防治合力。此外，吉利德科学支持的“创新引领 ...

以艾滋病为例，尽管随着药物创新和诊疗水平的不断提升，艾滋病已经成为可防可治的慢性疾病，但艾滋病仍是我国导致死亡人数最高的传染病。HIV感染者晚发现比例仍然较高、青年人群感染病例还在持续增加、地区防控水平存在明显差异、并发症问题严峻、社会对艾滋病的污名 ...

We need nothing less than disruptive action to ensure everyone who wants access to affordable lenacapavir can get it.

Gilead (GILD) announced the upcoming presentation of HIV research findings at the International Congress on Drug Therapy in HIV Infection, ...

Gilead Sciences, Inc. GILD reported better-than-expected third-quarter results and raised its annual earnings guidance.

特别引人关注的是，全球生物药物巨头吉利德（Gilead）首次在中国隆重推出了针对“隐形杀手”——原发性胆汁性胆管炎（PBC）的新药Seladelpar，以及革命性HIV长效治疗药物Lenacapavir。 背景：肝脏的隐形杀手 原发性胆汁性胆管炎（PBC）是一种慢性自身免疫性疾病 ...

Despite a mission to become a dominant cancer drug player, Gilead Sciences has as of late been locked in on its ...

BMO Capital Markets analyst Evan Seigerman in a note to investors called Gilead’s third-quarter performance “consistent” and ...